- cafead   Jul 12, 2024 at 11:52: AM
via AbbVie’s Humira (adalimumab) remains the biggest player in the anti-inflammatory space but its market share has dropped to 82% since May 2024, according to Samsung Bioepis’ latest biosimilar report released on Thursday.
article source
article source